• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因改变可区分不同类型的卵巢肿瘤。

Genetic alterations distinguish different types of ovarian tumors.

作者信息

Pieretti M, Cavalieri C, Conway P S, Gallion H H, Powell D E, Turker M S

机构信息

Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington 40536, USA.

出版信息

Int J Cancer. 1995 Dec 20;64(6):434-40. doi: 10.1002/ijc.2910640614.

DOI:10.1002/ijc.2910640614
PMID:8550247
Abstract

Seventy-four sporadic ovarian tumors were studied for loss of heterozygosity (LOH) and microsatellite instability (MI) with 20 polymorphic markers on chromosome 17 and at least I marker on every other chromosome. Additionally, activation of the K-ras oncogene was examined through mutation analysis of codon 12. A majority of the tumors analyzed were low grade and/or of the mucinous histologic type. A negative correlation between LOH on chromosome 17 and K-ras activation was observed, with the former alteration present in the majority of high grade serous and endometrioid tumors and the latter most commonly found in the mucinous and low malignant potential (LMP) tumors. In 60% of cases where LOH on chromosome 17 was present, it was observed at all informative markers, indicating chromosome loss. In these cases, frequent events of LOH were observed on the other chromosomes. When confined events of LOH were observed on chromosome 17, fewer events of LOH were observed on the other chromosomes. In the absence of LOH on chromosome 17, LOH on other chromosomes was rare. K-ras activation was most commonly observed in tumors with no LOH events. Two endometrioid tumors and 2 mucinous tumors demonstrated MI. Our data support the involvement of different molecular pathways in the development of different types of ovarian tumors.

摘要

对74例散发性卵巢肿瘤进行了杂合性缺失(LOH)和微卫星不稳定性(MI)研究,使用了17号染色体上的20个多态性标记以及其他每条染色体上至少1个标记。此外,通过对密码子12的突变分析检测了K-ras癌基因的激活情况。分析的大多数肿瘤为低级别和/或黏液性组织学类型。观察到17号染色体上的LOH与K-ras激活之间呈负相关,前一种改变存在于大多数高级别浆液性和子宫内膜样肿瘤中,而后一种最常见于黏液性和低恶性潜能(LMP)肿瘤中。在17号染色体存在LOH的60%的病例中,在所有信息性标记处均观察到LOH,表明存在染色体丢失。在这些病例中,在其他染色体上观察到频繁的LOH事件。当在17号染色体上观察到局限性的LOH事件时,在其他染色体上观察到的LOH事件较少。在17号染色体不存在LOH的情况下,其他染色体上的LOH很少见。K-ras激活最常见于无LOH事件的肿瘤中。2例子宫内膜样肿瘤和2例黏液性肿瘤表现出MI。我们的数据支持不同分子途径参与不同类型卵巢肿瘤的发生发展。

相似文献

1
Genetic alterations distinguish different types of ovarian tumors.基因改变可区分不同类型的卵巢肿瘤。
Int J Cancer. 1995 Dec 20;64(6):434-40. doi: 10.1002/ijc.2910640614.
2
Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium.卵巢和子宫内膜同步子宫内膜样肿瘤中的杂合性缺失和基因组不稳定性。
Cancer. 1995 Aug 15;76(4):650-7. doi: 10.1002/1097-0142(19950815)76:4<650::aid-cncr2820760417>3.0.co;2-1.
3
Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation.上皮性卵巢肿瘤中17号染色体长臂杂合性缺失:与浆液性分化癌的关联。
Int J Gynecol Pathol. 2000 Apr;19(2):152-7. doi: 10.1097/00004347-200004000-00009.
4
Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors.
Hum Pathol. 1995 Apr;26(4):393-7. doi: 10.1016/0046-8177(95)90139-6.
5
Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.卵巢癌的异质性:组织学类型、疾病分期、肿瘤标志物、患者特征与生存之间的关系。
Cancer Invest. 2002;20(1):11-23. doi: 10.1081/cnv-120000361.
6
Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas.浆液性和黏液性卵巢癌中K-RAS原癌基因的突变及6q27杂合性缺失
Cancer Genet Cytogenet. 2000 Apr 15;118(2):132-5. doi: 10.1016/s0165-4608(99)00192-2.
7
Comprehensive allelotype study of ovarian tumors of low malignant potential: potential differences in pathways between tumors with and without genetic predisposition to invasive carcinoma.低恶性潜能卵巢肿瘤的全面等位基因分型研究:有和无侵袭性癌遗传易感性的肿瘤之间潜在的途径差异。
Int J Cancer. 2001 Nov;94(4):605-9. doi: 10.1002/ijc.1499.
8
Microsatellite analysis in serous tumors of the ovary.卵巢浆液性肿瘤中的微卫星分析
Int J Gynecol Pathol. 1999 Apr;18(2):158-62. doi: 10.1097/00004347-199904000-00010.
9
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.在子宫内膜样上皮性卵巢肿瘤中频繁出现PTEN/MMAC突变,而浆液性或黏液性上皮性卵巢肿瘤中则不然。
Cancer Res. 1998 May 15;58(10):2095-7.
10
Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.等位基因分型确定了非浆液性上皮性卵巢癌中17q25染色体区域的最小失衡。
Oncogene. 2000 Mar 9;19(11):1466-72. doi: 10.1038/sj.onc.1203463.

引用本文的文献

1
Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.卵巢癌管理中的表观遗传生物标志物:当前展望
Front Cell Dev Biol. 2019 Sep 19;7:182. doi: 10.3389/fcell.2019.00182. eCollection 2019.
2
Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.在一个卵巢癌细胞系中过表达 CCL2 趋化因子可导致体内肿瘤生成能力的潜伏。
Oncogenesis. 2012 Sep 10;1(9):e27. doi: 10.1038/oncsis.2012.25.
3
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
来自与患者预后相关的明确起源人群的 TP53 和 p53 注释高级别卵巢浆液性癌的基因组景观。
PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20.
4
Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA.应用 MS-MLPA 技术对视网膜母细胞瘤进行表观遗传学和拷贝数变异分析。
Pathol Oncol Res. 2012 Jul;18(3):703-12. doi: 10.1007/s12253-012-9498-8. Epub 2012 Jan 26.
5
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.BRCA1相关卵巢癌中17号染色体缺失的基因组结构
Cancer Genet Cytogenet. 2008 May;183(1):41-8. doi: 10.1016/j.cancergencyto.2008.02.004.
6
Molecular mechanisms of resistance and toxicity associated with platinating agents.与铂类药物相关的耐药性和毒性的分子机制。
Cancer Treat Rev. 2007 Feb;33(1):9-23. doi: 10.1016/j.ctrv.2006.09.006. Epub 2006 Nov 3.
7
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.β微管蛋白突变和错配修复缺陷在卵巢癌对紫杉醇/顺铂耐药中无显著作用。
BMC Cancer. 2005 Aug 11;5:101. doi: 10.1186/1471-2407-5-101.
8
Molecular genetics of ovarian cancer.卵巢癌的分子遗传学
Mol Biotechnol. 2001 Sep;19(1):13-28. doi: 10.1385/MB:19:1:013.
9
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene.小窝蛋白-1在人类卵巢癌中表达下调,并作为一种候选肿瘤抑制基因发挥作用。
Am J Pathol. 2001 Nov;159(5):1635-43. doi: 10.1016/S0002-9440(10)63010-6.
10
A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer.基于顺铂的卵巢癌化疗引起的微卫星不稳定性变化。
Br J Cancer. 2001 Sep 28;85(7):1064-9. doi: 10.1054/bjoc.2001.2037.